TR201204839A2 - Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu. - Google Patents

Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.

Info

Publication number
TR201204839A2
TR201204839A2 TR2012/04839A TR201204839A TR201204839A2 TR 201204839 A2 TR201204839 A2 TR 201204839A2 TR 2012/04839 A TR2012/04839 A TR 2012/04839A TR 201204839 A TR201204839 A TR 201204839A TR 201204839 A2 TR201204839 A2 TR 201204839A2
Authority
TR
Turkey
Prior art keywords
entacapone
formulation containing
tablet formulation
prolonged release
carbidopa
Prior art date
Application number
TR2012/04839A
Other languages
English (en)
Inventor
Kesgi̇n Di̇dehan
Bulgur Abdullah
Original Assignee
Ali̇ Rai̇f İlaç Sanayi̇ A.Ş.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. filed Critical Ali̇ Rai̇f İlaç Sanayi̇ A.Ş.
Priority to TR2012/04839A priority Critical patent/TR201204839A2/tr
Publication of TR201204839A2 publication Critical patent/TR201204839A2/tr
Priority to EP13002069.6A priority patent/EP2656856A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Levodopa, karbidopa, entakapon veya bu moleküllerin farmasötik olarak kabul edilebilir tuzlarını, solvatlarını veya hidratlarını, levodopa ve karbidopayı kombine formda uzun etkili, entakaponu ıse hemen salım formunda içeren ve salım kontrol eden bir polimer olarak polietilen oksit ve bir organik asit içeren, Parkinson hastalığının tedavisi amaçlı bir kompozisyon ile ilgilidir.
TR2012/04839A 2012-04-25 2012-04-25 Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu. TR201204839A2 (tr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2012/04839A TR201204839A2 (tr) 2012-04-25 2012-04-25 Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
EP13002069.6A EP2656856A3 (en) 2012-04-25 2013-04-19 Tablet formulation comprising levodopa, carbidopa, entacapone providing extended release

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2012/04839A TR201204839A2 (tr) 2012-04-25 2012-04-25 Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.

Publications (1)

Publication Number Publication Date
TR201204839A2 true TR201204839A2 (tr) 2012-12-21

Family

ID=47679809

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2012/04839A TR201204839A2 (tr) 2012-04-25 2012-04-25 Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.

Country Status (2)

Country Link
EP (1) EP2656856A3 (tr)
TR (1) TR201204839A2 (tr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65060B1 (sr) * 2014-03-13 2024-02-29 Neuroderm Ltd Sastavi inhibitora dopa dekarboksilaze
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ220599A (en) 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US5840756A (en) 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US6531153B2 (en) 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20060222703A1 (en) * 2005-04-01 2006-10-05 Iprbox Oy Pharmaceutical composition and preparation method thereof
US20070003621A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Dosage forms for movement disorder treatment
EP2104424A4 (en) 2006-10-30 2011-06-15 Wockhardt Research Center PHARMACEUTICAL COMPOSITIONS COMPRISING ENTACAPONE, LEVODOPA, AND CARBIDOPA
JP5466179B2 (ja) * 2008-02-06 2014-04-09 ウォックハート リサーチ センター 生物学的利用能が改善されたエンタカポン、レボドパ及びカルビドパの医薬組成物
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar

Also Published As

Publication number Publication date
EP2656856A2 (en) 2013-10-30
EP2656856A3 (en) 2014-07-09

Similar Documents

Publication Publication Date Title
CY1122187T1 (el) Αντιγονικη συνθεση μυκοβακτηριου
PH12015501265A1 (en) Composition with zinc amino acid/trimenthylglycine halide precursors
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
TR201204839A2 (tr) Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
MX2014011153A (es) Polimeros superabsorbentes y elastomero de silicona para usar en composiciones para el cuidado del cabello.
MY162146A (en) Pharmaceutical composition
PH12015501982A1 (en) Pharmaceutical compositions comprising everolimus
GEP20196969B (en) New therapeutical composition containing apomorphine as active ingredient
MX367560B (es) Composicion cosmetica.
MX2015007384A (es) Antitranspirante/desodorante con polivinilpirrolidona alquilada.
CL2015001748A1 (es) Formulaciones antiparasitarias transdermicas
EA201291276A1 (ru) Фармацевтические композиции, содержащие солифенацин
MX2016008211A (es) Composiciones para cuidado oral y metodos.
EA201390980A1 (ru) Лекарственный пластырь для улучшенного трансдермального проникновения диклофенака диэтиламмония
MX2015008171A (es) Formulacion que comprende agomelatina amorfa.
BR112015014109A2 (pt) preparação cosmética ou dermatológica; e uso de sais de zinco de ácidos carboxílicos, em combinação com um ou mais compostos de eficácia antimicrobiana e/ou antiperspirante
MX363558B (es) Composiciones farmaceuticas que comprenden flurbiprofeno.
EA201201329A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
CY1118117T1 (el) Νεα αμινο-πυρρολινικα παραγωγα και η χρηση τους στην προληψη ή και τη θεραπεια του μεταβολικου συνδρομου
IN2014MN02651A (tr)
TR201109159A2 (tr) Eplerenon içeren film kaplı tablet kompozisyonu.
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
TR201204288A2 (tr) Levodopa, karbidopa, entakapon içeren tablet formülasyonu.
MY192061A (en) Pharmaceutical composition for external use
MX2015008757A (es) Formulaciones de lorazepam de liberacion controlada.